Cytori Therapeutics (NASDAQ:CYTX) today received U.S. Patent No.
7,651,684 (the ‘684 patent) which covers the Company’s methods for
delivering adipose-derived stem and regenerative cell-enriched fat
grafts into patients. The ‘684 patent specifically covers cell-enriched
fat grafts to treat soft-tissue defects and urinary incontinence. In
addition, the ‘684 patent covers methods for delivering cell-enriched
fat grafts to a patient’s breast, wrinkles, lips, under the eyes,
cheeks, chin, and other parts of the body.
“Today’s announcement broadens our current expansive patent portfolio
covering adipose-derived cell therapies. The patent covers many
significant applications for stem and regenerative cell-enriched fat
grafting, allowing us to freely develop future generation therapeutics
and pursue solutions for patients with unmet medical needs in tissue
damage indications, including breast reconstruction”
“Today’s announcement broadens our current expansive patent portfolio
covering adipose-derived cell therapies. The patent covers many
significant applications for stem and regenerative cell-enriched fat
grafting, allowing us to freely develop future generation therapeutics
and pursue solutions for patients with unmet medical needs in tissue
damage indications, including breast reconstruction,” said Christopher
J. Calhoun, CEO of Cytori Therapeutics.